ApoB (Apolipoprotein B) (ApoB)
Also known as: ApoB
ApoB measures the number of atherogenic lipoprotein particles in circulation. It is a stronger predictor of cardiovascular events than LDL-C alone and is increasingly the preferred cardiovascular risk biomarker.
What ApoB (Apolipoprotein B) measures
Apolipoprotein B (ApoB) counts the number of atherogenic lipoprotein particles in circulation. Each VLDL, IDL, LDL, and Lp(a) particle carries exactly one ApoB molecule, so ApoB is a direct particle count — the most accurate single lipid measurement for cardiovascular risk.
Clinical significance
ApoB out-performs LDL-C and non-HDL-C for ASCVD risk prediction, especially in patients with metabolic syndrome, insulin resistance, hypertriglyceridemia, or discordant lipids. Two patients with identical LDL-C can have very different ApoB and therefore very different cardiovascular trajectories.
How oMeds reviews it
ApoB is the lead cardiovascular marker in oMeds optimization. It is paired with Lp(a), hs-CRP, triglycerides, and HDL to characterize atherogenic burden. Optimization targets ApoB bands tighter than ASCVD population thresholds, recognizing that lifetime exposure is what compounds.
Standard clinical reference intervals
Lab-reported reference ranges from established standards bodies. These are diagnostic thresholds — they do not represent optimization targets.
Source: AACC adult optimal reference (<90 mg/dL primary prevention)
oMeds optimization targets
Editorial bands that inform provider-reviewed conversations. These are wellness targets, not diagnostic thresholds.
Cumulative ApoB exposure is the cleanest predictor of atherosclerotic plaque accumulation; provider-reviewed optimization targets the lower portion of the reference range when tolerated.
oMeds optimization ranges are editorial targets that inform conversations with a licensed provider. They are NOT diagnostic thresholds and do not replace lab reference ranges.
ApoB (Apolipoprotein B) — frequently asked
ApoB or LDL-C — which is right?
ApoB when available. It counts particles directly; LDL-C estimates cholesterol content inside particles. They agree most of the time, but ApoB is more accurate when they don't.
Do I need ApoB if my LDL is fine?
Often, yes — particularly with insulin resistance, hypertriglyceridemia, or a strong family history. Provider review adds ApoB when LDL-C alone could under-state risk.
Source literature
- ApoB and ASCVD risk (Sniderman et al.) · JAMA Cardiology
- 2019 ESC/EAS Dyslipidaemia Guidelines · European Heart Journal
How this entity relates
Every entity in the oMeds knowledge graph cross-links to the conditions, biomarkers, medications, and educational surfaces it touches.
Explore Related Biomarkers
Related Optimization Resources
Recommended Next Step
Take the Universal AssessmentBring this entity into your optimization pathway
Every condition, symptom, biomarker, and medication on oMeds is reviewed by a licensed provider and recalibrated against the standardized biomarker panel.